{"id":211614,"name":"ACCELERON PHARMA, INC","slug":"acceleron-pharma-inc","state":"MA","country":"United States of America","description":"Rare disease drug discovery and development","totalSpending":90000,"filings":4,"yearlySpending":[{"year":2021,"income":60000},{"year":2022,"income":30000}],"issues":[{"code":"PHA","display":"Pharmacy"},{"code":"MMM","display":"Medicare/Medicaid"},{"code":"HCR","display":"Health Issues"},{"code":"TAX","display":"Taxation/Internal Revenue Code"}],"firms":["SPLITOAK STRATEGIES LLC"],"lobbyists":["AMY JENSEN","SARAH EGGE"],"govEntities":["HOUSE OF REPRESENTATIVES","SENATE"],"sampleDescriptions":["Rare disease patient access to needed therapies (HR 3), Value of Medicare Parts B and D","HR 3, Impact on rare disease research","HR 3, impact on rare disease research","HR 5376, Build Back Better Act-impact on rare disease research","HR 5376, Build Back Better Act-impact on rare disease research"]}